Breaking Finance News

Catalent Inc (NASDAQ:CTLT) stock price target increased to $25.00, issued a ratings update today by Goldman Sachs Group Inc.

In a report released on 12/01/2016 Goldman Sachs Group Inc. upped the price target of Catalent Inc (NASDAQ:CTLT) to $25.00 stating a potential upside of 0.04%.

Boasting a price of $23.93, Catalent Inc (NASDAQ:CTLT) traded -3.59% lower on the day. With the last stock price close down -6.71% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.03% over the date range. Catalent Inc has recorded a 50-day average of $24.20 and a two hundred day average of $24.73. Volume of trade was down over the average, with 415,671 shares of CTLT changing hands under the typical 1,247,810

Performance Chart

Catalent Inc (NASDAQ:CTLT)

With a total market value of $0, Catalent Inc has price-earnings ratio of 27.63 with a one year low of $18.92 and a one year high of $32.24 .

A total of 6 equity analysts have released a ratings update on CTLT. zero equity analysts rating the company a strong buy, zero equity analysts rating the company a buy, zero equity analysts rating the company a hold, zero equity analysts rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of $27.92.

Brief Synopsis About Catalent Inc (NASDAQ:CTLT)

Catalent, Inc. provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels. The Drug Delivery Solutions segment is engaged in the formulation, development and manufacturing of prescription and consumer and animal health products; blow-fill seal unit dose manufacturing; biologic cell line development; analytical and bioanalytical development, and testing services. The Clinical Supply Services segment is engaged in manufacturing, packaging, labeling, storage, distribution and inventory management for clinical trials of drugs and biologics for patient kits; FastChain clinical supply service; clinical e-solutions and informatics, and global comparator sourcing services.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *